Literature DB >> 19502551

Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models.

Pia J Guinto1, Todd E Haim, Candice C Dowell-Martino, Nathaniel Sibinga, Jil C Tardiff.   

Abstract

Naturally occurring mutations in cardiac troponin T (cTnT) result in a clinical subset of familial hypertrophic cardiomyopathy. To determine the mechanistic links between thin-filament mutations and cardiovascular phenotypes, we have generated and characterized several transgenic mouse models carrying cTnT mutations. We address two central questions regarding the previously observed changes in myocellular mechanics and Ca(2+) homeostasis: 1) are they characteristic of all severe cTnT mutations, and 2) are they primary (early) or secondary (late) components of the myocellular response? Adult left ventricular myocytes were isolated from 2- and 6-mo-old transgenic mice carrying missense mutations at residue 92, flanking the TNT1 NH(2)-terminal tail domain. Results from R92L and R92W myocytes showed mutation-specific alterations in contraction and relaxation indexes at 2 mo with improvements by 6 mo. Alterations in Ca(2+) kinetics remained consistent with mechanical data in which R92L and R92W exhibited severe diastolic impairments at the early time point that improved with increasing age. A normal regulation of Ca(2+) kinetics in the context of an altered baseline cTnI phosphorylation suggested a pathogenic mechanism at the myofilament level taking precedence for R92L. The quantitation of Ca(2+)-handling proteins in R92W mice revealed a synergistic compensatory mechanism involving an increased Ser16 and Thr17 phosphorylation of phospholamban, contributing to the temporal onset of improved cellular mechanics and Ca(2+) homeostasis. Therefore, independent cTnT mutations in the TNT1 domain result in primary mutation-specific effects and a differential temporal onset of altered myocellular mechanics, Ca(2+) kinetics, and Ca(2+) homeostasis, complex mechanisms which may contribute to the clinical variability in cTnT-related familial hypertrophic cardiomyopathy mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19502551      PMCID: PMC2724218          DOI: 10.1152/ajpheart.01143.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  53 in total

Review 1.  From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease.

Authors:  R L Nicol; N Frey; E N Olson
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

2.  Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport.

Authors:  Donald M Bers; David A Eisner; Hector H Valdivia
Journal:  Circ Res       Date:  2003-09-19       Impact factor: 17.367

3.  Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation.

Authors:  Murali Chandra; Matthew L Tschirgi; Jil C Tardiff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-01       Impact factor: 4.733

4.  Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy.

Authors:  B C Knollmann; J D Potter
Journal:  Trends Cardiovasc Med       Date:  2001-07       Impact factor: 6.677

Review 5.  Regulation of cardiac contractile function by troponin I phosphorylation.

Authors:  Joanne Layland; R John Solaro; Ajay M Shah
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

Review 6.  Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias.

Authors:  Mark E Anderson
Journal:  Pharmacol Ther       Date:  2005-01-12       Impact factor: 12.310

7.  Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy.

Authors:  C C Evans; J R Pena; R M Phillips; M Muthuchamy; D F Wieczorek; R J Solaro; B M Wolska
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-11       Impact factor: 4.733

8.  Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.

Authors:  Björn C Knollmann; Paulus Kirchhof; Syevda G Sirenko; Hubertus Degen; Anne E Greene; Tilmann Schober; Jessica C Mackow; Larissa Fabritz; James D Potter; Martin Morad
Journal:  Circ Res       Date:  2003-02-06       Impact factor: 17.367

9.  Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics.

Authors:  Todd E Haim; Candice Dowell; Theodhor Diamanti; James Scheuer; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2007-03-31       Impact factor: 5.000

10.  Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium.

Authors:  Bradley M Palmer; David E Fishbaugher; Joachim P Schmitt; Yuan Wang; Norman R Alpert; Christine E Seidman; J G Seidman; Peter VanBuren; David W Maughan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-03-04       Impact factor: 4.733

View more
  37 in total

1.  HCM-linked ∆160E cardiac troponin T mutation causes unique progressive structural and molecular ventricular remodeling in transgenic mice.

Authors:  Rachel K Moore; Lauren Tal Grinspan; Jesus Jimenez; Pia J Guinto; Briar Ertz-Berger; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2013-02-19       Impact factor: 5.000

2.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

3.  Accurate quantitation of phospholamban phosphorylation by immunoblot.

Authors:  Naa-Adjeley Ablorh; Tyler Miller; Florentin Nitu; Simon J Gruber; Christine Karim; David D Thomas
Journal:  Anal Biochem       Date:  2012-02-03       Impact factor: 3.365

Review 4.  Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential.

Authors:  Brian R Thompson; Joseph M Metzger
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

5.  The Role of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Hypertrophic Cardiomyopathy.

Authors:  Jil C Tardiff
Journal:  Circulation       Date:  2016-11-29       Impact factor: 29.690

6.  Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.

Authors:  Sarah J Lehman; Lauren Tal-Grinspan; Melissa L Lynn; Joshua Strom; Grace E Benitez; Mark E Anderson; Jil C Tardiff
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

7.  Atomic resolution probe for allostery in the regulatory thin filament.

Authors:  Michael R Williams; Sarah J Lehman; Jil C Tardiff; Steven D Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

8.  Cardiac myosin heavy chain isoform exchange alters the phenotype of cTnT-related cardiomyopathies in mouse hearts.

Authors:  Ron Rice; Pia Guinto; Candice Dowell-Martino; Huamei He; Kirsten Hoyer; Maike Krenz; Jeffrey Robbins; Joanne S Ingwall; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2009-12-31       Impact factor: 5.000

9.  Myosin-driven rescue of contractile reserve and energetics in mouse hearts bearing familial hypertrophic cardiomyopathy-associated mutant troponin T is mutation-specific.

Authors:  Huamei He; Kirsten Hoyer; Hai Tao; Ronald Rice; Jesus Jimenez; Jil C Tardiff; Joanne S Ingwall
Journal:  J Physiol       Date:  2012-08-20       Impact factor: 5.182

10.  Sexually dimorphic myofilament function and cardiac troponin I phosphospecies distribution in hypertrophic cardiomyopathy mice.

Authors:  Laurel A K McKee; Hao Chen; Jessica A Regan; Samantha M Behunin; Jeffery W Walker; John S Walker; John P Konhilas
Journal:  Arch Biochem Biophys       Date:  2013-01-23       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.